Status:
COMPLETED
Oral Nutritional Supplementation With HMB Enhance Muscle Quality in Sarcopenic Surgical Patients
Lead Sponsor:
Sengkang General Hospital
Collaborating Sponsors:
Abbott
Conditions:
Sarcopenia
Frailty
Eligibility:
All Genders
40-90 years
Phase:
NA
Brief Summary
Aims: Clinical frailty severely impacts the physical, functional and physiological reserves necessary for the recovery after surgery. Sarcopenia, a multifactorial, multi-organ process which lead to l...
Eligibility Criteria
Inclusion
- between 40-90 years old
- are sarcopenia (defined by the Asian Workgroup of Sarcopenia 2019 definition)
- due to undergo elective major gastrointestinal surgery
- able to satisfy at least 2 weeks of prehabilitation before surgery
- ambulant
- able to comply with physiotherapy and dietician advice
Exclusion
- Are pregnant
- Are prisoners
- Intellectually, mentally or emotionally deemed not able to provide an informed consent and/or are unable to fill up the post-procedure questionnaires
- Have disease conditions requiring emergent/semi-emergent operation
- Diabetes on oral hyperglycemic agents (OHGA)
- Chronic Kidney Disease (CKD) or End-stage Renal Failure (ESRF)
- Unable to or decline assessment for sarcopenia
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2024
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT05344313
Start Date
June 1 2022
End Date
June 30 2024
Last Update
October 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sengkang General Hospital
Singapore, Singapore, 544886